28 results about "Precursor cell" patented technology

The present invention relates to compositions comprising photoreceptor precursor cells (PRPs), as well as methods of generating the composition of PRPs and methods of using the composition of PRPs for regenerative cell therapy.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

The present application relates to a preparation method and application of photoreceptor precursor cells of human embryonic stem cell-derived retinal organoids, and belongs to the field of biotechnology and stem cell engineering. The present application constructs a lentiviral vector carrying an exogenous target gene and infects human embryonic stem cells to obtain a stable expression of engineered stem cell clone group by screening; the clone group is subjected to three-dimensional differentiation, and sequentially undergoes the formation of a blastoid, neural epithelial induction and retinal layering stage to obtain a retinal organoid; finally, the co-expression of photoreceptor precursor cell markers and exogenous genes in the organoid is identified. The present application realizes stable integration of genes at the source of stem cells, avoids the problem of low infection efficiency in the later stage, and provides a complete standardized scheme from gene modification, directional differentiation to function verification. The engineered photoreceptor precursor cells obtained by the method have important application value in the construction of retinal disease models, drug screening and cell therapy development.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

Provided is a method for production by direct transdifferentiation of somatic cells into another somatic cells which is convenient, has good reproducibility, is excellent in production efficiency, and is performed in a short period of time. The method for production by direct transdifferentiation of somatic cells into another somatic cells comprises: (a) a step of introducing a GLIS family gene, a mutated GLIS family gene or a gene product thereof into somatic cells; and (b) a step of culturing the gene-introduced somatic cells in a culture medium containing a component that induces differentiation of the somatic cells or precursor cells of the somatic cells into another somatic cells.

The present application relates to a kind of pig hair follicle matrix precursor cell identification method and its application.The present application uses OGN and UCHL1 as the marker gene of pig hair follicle matrix precursor cell, the gene number of the OGN in NCBI database is 106509723, the gene number of the UCHL1 in NCBI database is 396637, the identification method is: pig embryo epidermal cell is immunofluorescence dyeing, OGN and UCHL1 can be simultaneously detected cell is pig hair follicle matrix precursor cell, the pig embryo refers to the embryo of pig embryo period 37 days and before.This application provides the identification method of pig hair follicle matrix precursor cell, and is applied in hair follicle development research.The present application discloses that OGN and UCHL1 are more suitable as the marker gene of pig hair follicle matrix precursor cell than BMP7 and TGF beta 2.

This disclosure relates to an MLPSC-mediated method for treating congenital heart disease. Such methods may be particularly suitable for treating subjects with hypoplastic left ventricular syndrome.

This application discloses a hepatocyte spheroid, a hepatocyte spheroid formulation, its preparation method, and its application. Hepatic progenitor cells are seeded onto microcarriers and cultured in 3D under oxygen conditions. The microcarriers are then degraded using digestive enzymes to obtain hepatocyte progenitor cell clusters. These clusters are then cultured in a 3D reactor with stirring, and induced to differentiate in serum-free hepatocyte culture medium to obtain hepatocyte spheroids. The hepatocyte progenitor cell clusters of this application are cryopreserved and spontaneously spheroidize upon thawing before use. The induction into a hepatocyte spheroid formulation takes only about one week, resulting in higher spheroidization efficiency, less cell loss, and higher thawing viability, meeting clinical treatment needs. Fresh formulations can be directly used for the clinical treatment of various chronic, chronic-onset, and acute liver diseases. Compared to single cells, these spheroids exhibit longer and more stable survival periods in vivo and in vitro, as well as better storage, transportation, and usage stability. Preparation is also simpler, requiring no cell digestion or other procedures.

The application belongs to the technical field of biotechnology, and particularly relates to a culture medium for preparing a 3D heart organoid and a preparation method of the 3D heart organoid. The components in the culture medium provided by the application have a synergistic effect, the CM-1 culture medium enables 3D cell balls to form a primitive germ layer structure in the culture medium, the CM-2 culture medium promotes differentiation of myocardial precursor cells into functional myocardial cells, the CM-3 culture medium helps to form a contraction structure of mature myocardial cells and supports functional maturation, and the CM-4 culture medium improves cell viability in the process of induction and differentiation, as well as structural stability and functional maturation of the 3D heart organoid. By using the culture medium provided by the application, the 3D heart organoid can be prepared in a 3D dynamic environment, a 2D culture step is skipped, operation complexity is reduced, bionics is improved, and a 3D heart organoid culture period is shortened.

This invention discloses the application of α-ketoglutarate in the preparation of agents that promote oligodendrocyte precursor cell differentiation, belonging to the field of biomedical technology. This invention is the first to use α-ketoglutarate in the preparation of drugs for the prevention and / or treatment of OPC differentiation disorders. Experimental results show that exogenous supplementation with α-ketoglutarate or its derivatives can regulate the differentiation level of OPCs under physiological conditions, effectively promote OPC differentiation, and improve symptoms such as decreased motor function and shortened lifespan caused by OPC differentiation defects. It demonstrates good efficacy and safety, and possesses high clinical application value.

The invention relates to products and methods for transdifferentiating oligodendrocytes and / or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

Mesenchymal stem cells and osteoblast progenitor cells are induced to differentiate into osteoblasts. Provided is a culture medium for stem cell culture containing 60 vol% to 90 vol% of a basal culture medium and 10 vol% to 40 vol% of physiological saline, and further having, added thereto, 1 ng / mL to 100 ng / mL of EGF, 0.2 ng / mL to 20.0 ng / mL of FGF-2, 0.2 ng / mL to 20.0 ng / mL of PDGF, and 0.5 mM to 8.0 mM of magnesium ascorbyl phosphate.

This invention provides a concentration gradient cell culture system that solves the problem of large errors in manual drug addition and the difficulty in constructing a stable, continuous concentration gradient in studies on the control of osteoclast progenitor cell differentiation using propionic acid-GPR43. [Solution] The system comprises a housing assembly with an inner container, a first liquid storage cylinder 2, a second liquid storage cylinder 3, a tuned crossbeam 4, an adjustable screw rod 5, a flow-dividing branch pipe array frame, a spiral mixing unit, a porous diffusion plate, and a culture tray 9. The tuned crossbeam is driven by the adjustable screw rod to synchronously supply liquid from both liquid storage cylinders. After gradient distribution by the flow-dividing branch pipe array frame and mixing by the spiral mixing unit, the porous diffusion plate forms a continuous and stable propionic acid concentration gradient field on the culture tray. This avoids manual errors, provides accurate concentration gradients to RAW264.7 and BMMs cells in a single experiment, and supports the calculation of dose-effect curves and IC50, as well as the elucidation of the mechanism of osteoclast differentiation control by propionic acid-GPR43 signaling.

The application discloses an intermediate module molecule for activating chimeric antigen receptor effector cells and application thereof, and belongs to the field of biological medicine. The application focuses on developing an intermediate module molecule capable of regulating the activity of chimeric antigen receptor T cells and capable of regulating the interaction between chimeric antigen receptor T cells and target cells. The module molecule comprises: (a) a targeting polypeptide, which is a tumor target binding polypeptide; (b) an exogenous tag molecule, which is capable of being combined with a chimeric antigen receptor on an effector cell, and (C) a linker connecting the targeting polypeptide and the exogenous tag molecule; and the effector cell is selected from the group consisting of dendritic cells, killer dendritic cells, mast cells, natural killer cells, B lymphocytes, T lymphocytes, macrophages and precursor cells thereof.

The present invention relates to compositions for cellular reprogramming of human somatic cells into induced oligodendrocyte precursor cells, methods of making human induced oligodendrocyte precursor cells by cellular reprogramming and methods of using reprogramed human induced oligodendrocyte precursor cells for treating disease.

The present invention relates to compositions comprising photoreceptor precursor cells (PRPs), as well as methods of generating the composition of PRPs and methods of using the composition of PRPs for regenerative cell therapy.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

Certain populations of small cells present in adult human tissue can undergo activation / development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation / development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

A method of treating lower back pain in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs), wherein the lower back pain is associated with an intervertebral disc that has a disc height that is not substantially reduced compared to that of an adjacent healthy disc in the subject. 20 26 20 47 17 18 J un 2 02 6 A B S T R A C T 2 0 2 6 2 0 4 7 1 7 1 8 J u n 2 0 2 6

The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine. Lastly, the application relates to in vitro methods in which the skeletal muscle tissue or the disclosed cells are used.

The present invention relates to the treatment of inherited retinal diseases using stem cell therapy. In particular, the present disclosure relates to methods of using photoreceptor precursor cells to treat primary photoreceptor diseases via surgical administration to the eye of a subject.

This invention discloses the application of a PITPα regulator in the preparation of drugs for white matter remyelination repair. This invention increases the expression level of phospholipid transporter α (PITPα) in oligodendrocyte precursor cells by using a PITPα regulator, promoting oligodendrocyte maturation, differentiation, and remyelination, thereby improving white matter structure and neurological function outcomes after ischemic brain injury. The PITPα regulator used is a lipid nanoparticle encapsulating PITPα mRNA, or further, a targeting ligand for oligodendrocyte precursor cells is attached to the surface of the lipid nanoparticle. This invention provides a novel treatment strategy for ischemic brain injury.

An example system for cancer metastasis detection and risk prediction includes a cell identification module and a risk prediction module, where the risk prediction module is configured to analyze identified cell types and assess the likelihood of metastasis. An example computer-implemented method includes receiving a sample, identifying cancer metastatic and precursor cell types using a cell identification module, predicting the risk of metastasis occurrence using a risk prediction module, and outputting the timing and location of potential metastasis.

The application provides application of GNAQ and GAP43 as protein markers in sorting brain motor functional neural precursor cells, and belongs to the technical field of biological cells. The application provides application of GNAQ and GAP43 as protein markers in sorting brain motor functional neural precursor cells (BMFNPC). Cell sorting is carried out by using the specific BMFNPC marker provided in the application, so that the cell purity of the BMFNPC can be significantly improved, batch difference can be reduced, and a high-purity and homogeneous BMFNPC cell population is obtained. The BMFNPC product prepared by using the sorting method provided in the application has high safety and effectiveness, and is conducive to transformation of the product to standardized and controllable clinical treatment.

The present invention application is related to a hepatic precursor cell and a method and an application for establishing a hepatic precursor cell line. The method for establishing a hepatic precursor cell line comprises: S0: preparing hepatic precursor cells, miscible liquids, and a reprogramming culture medium, wherein the miscible liquids comprises a serum-free medium, polyethyleneimine, and a CLP plasmid; S1: transfecting the hepatic precursor cells with the miscible liquids to obtain transduced hepatic precursor cells; and S2: passing the transduced hepatic precursor cells into the reprogramming culture medium for subculture to obtain immortalized hepatic precursor cells. The present invention application resolves the prior art limitations of immortalization genes, which cannot transform hepatic precursor cells into immortalized cell lines or enable sustained in vitro subculturing.

The present application relates to the technical field of genetic engineering and cell biology, and particularly relates to a universal human induced pluripotent stem cell, PD-L1 The promoter is inserted into a short enhancer sequence, the short enhancer sequence has the characteristics of enhancing the expression of PD-L1 when being differentiated into dopaminergic neural precursor cells or dopaminergic neuron cells, and the short enhancer sequence is selected from any one of TSE012, TSE026, TSE053, TSE075 and TSE089. The present application also relates to a ready-to-use mDAP / mDA cell and application, has cell type-specific immune escape, only when the cell is differentiated into mDAP / mDA, the expression of immune rejection genes PD-L1 and CTLA4 is started, has little influence on genomic stability, and in-situ activation of gene expression is realized.